EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study

Petter Bjornstad, Silva A Arslanian, Tamara S Hannon, Philip S Zeitler, Jennie L Francis, Alexandra M Curtis, Ibrahim Turfanda, David A Cox iD

Diabetes Care · 2024

DOI: 10.2337/dc24-0322 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, 2024. Verfasst von Petter Bjornstad und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Endocrinology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Proteinuria, Glomerular Filtration Rate, Albuminuria. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To examine changes in glomerular hyperfiltration and other measures of kidney function in youth with type 2 diabetes treated with dulaglutide or placebo. RESEARCH DESIGN AND METHODS Post hoc analysis was performed on kidney laboratory data from 154 youths (age 10–18 years) with type 2 diabetes enrolled in a completed placebo-controlled glycemic control trial of dulaglutide. RESULTS Mean estimated glomerular filtration rate (eGFR) decreased from baseline to 26 weeks in participants treated with dulaglutide versus placebo (−5.8 vs. −0.1 mL/min/1.73 m2; P = 0.016). Decreases in eGFR were observed primarily in participants with baseline glomerular hyperfiltration. At 26 weeks, the prevalence of both glomerular hyperfiltration and proteinuria increased with placebo but decreased with dulaglutide (P = 0.014 and 0.004 vs. placebo, respectively). CONCLUSIONS Dulaglutide was associated with attenuated glomerular hyperfiltration and proteinuria in youth with type 2 diabetes. The impact of these changes on the risk of diabetic kidney disease is unclear.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2ProteinuriaGlomerular Filtration RateAlbuminuriaRecombinant Fusion ProteinsGlucagon-Like PeptidesImmunoglobulin Fc FragmentsHumansAdolescentChildMaleFemaleHypoglycemic AgentsDiabetic Nephropathies

Substanzen

dulaglutideRecombinant Fusion ProteinsGlucagon-Like PeptidesImmunoglobulin Fc FragmentsHypoglycemic Agents

Autor:innen und Institutionen

  • Section of Endocrinology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO.
  • Center for Pediatric Research in Obesity and Metabolism, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center Children's Hospital of Pittsburgh, Pittsburgh, PA.
  • Center for Pediatric Obesity and Diabetes Prevention, Indiana University School of Medicine, Indianapolis, IN.
  • Eli Lilly and Company, Indianapolis, IN.

ORCID-Profile: David A Cox

Förderung

  • Eli Lilly and Company

Zitieren

APA

Bjornstad, P., Arslanian, S. A., Hannon, T. S., Zeitler, P. S., Francis, J. L., Curtis, A. M., Turfanda, I., & Cox, D. A. (2024). Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study. Diabetes Care. https://doi.org/10.2337/dc24-0322

Vancouver

Bjornstad P, Arslanian SA, Hannon TS, Zeitler PS, Francis JL, Curtis AM, et al. Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study. Diabetes Care. 2024. doi:10.2337/dc24-0322

BibTeX
@article{Bjornstad2024,
  author = {Bjornstad, Petter and Arslanian, Silva A and Hannon, Tamara S and Zeitler, Philip S and Francis, Jennie L and Curtis, Alexandra M and Turfanda, Ibrahim and Cox, David A},
  title = {Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study},
  journal = {Diabetes Care},
  year = {2024},
  doi = {10.2337/dc24-0322}
}
Kostenlos starten →